Our study confirmed adequate (12 months) trastuzumab therapy could prolong the survival of HER2+ breast cancer patients in terms of DFS (HR 0.49, 95% CI 0.29-0.85) and OS (HR 0.30, 95% CI 0.15-0.60) in the neoadjuvant setting. This evidence concerns the gene ERBB2 and breast cancer.